Kaigo Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kaigo Health (YC F25) deploys AI voice agents for elderly outpatient follow-up, scaling post-visit check-ins 100x for Medicare providers who currently have near-zero between-visit care.
About
Kaigo Health is a healthcare AI startup founded in 2025 and headquartered in San Francisco, built to address one of the most persistent gaps in outpatient elderly care: the near-complete absence of structured follow-up between clinical visits. The company was accepted into Y Combinator's Fall 2025 batch, a validation of its founding team and market thesis at a very early stage. Kaigo targets the Medicare provider ecosystem, where outpatient follow-up is both a quality metric and a reimbursement driver under value-based care arrangements.\n\nKaigo's platform deploys AI voice agents that conduct follow-up calls with elderly patients between clinical encounters, checking on medication adherence, symptom changes, and overall wellbeing in a conversational, accessible format appropriate for older adults who may be less comfortable with app-based or text communication. The system scales these follow-up touchpoints by 100x compared to what a human care coordination team could accomplish at equivalent cost, dramatically expanding the reach of providers who want to improve patient engagement without proportional staffing increases.\n\nThe company is entering a market shaped by twin pressures: an aging US population driving record Medicare enrollment and a care workforce shortage that makes scaling high-touch care coordination through humans alone economically unsustainable. AI voice agents are increasingly recognized as a practical solution to this gap, particularly for the elderly population where voice interaction is natural and phone calls remain a trusted communication channel. Kaigo's early YC backing positions it alongside a cohort of companies building AI infrastructure for the future of value-based elder care.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.